{
"info": {
"nct_id": "NCT00359476",
"official_title": "A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer",
"inclusion_criteria": "* Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxane-containing regimen in any combination in one prior first line treatment.\n* EGOC performance status of 0,1 or 2\n* Men and women, 18 years of age and older\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients having received more than one previous systemic chemotherapy regimen in any setting.\n* Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks\n* Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis)\n* Prior radiation to >=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment\n* Acute or chronic hepatitis\n* Known HIV infection\n* A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms\n* A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxane-containing regimen in any combination in one prior first line treatment.",
"criterions": [
{
"exact_snippets": "locally advanced or metastatic gastric adenocarcinoma",
"criterion": "gastric adenocarcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "adenocarcinoma of the gastroesophageal junction",
"criterion": "adenocarcinoma of the gastroesophageal junction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "progressed on a fluoropyrimidine or taxane-containing regimen",
"criterion": "progression on fluoropyrimidine or taxane-containing regimen",
"requirements": [
{
"requirement_type": "progression",
"expected_value": true
}
]
},
{
"exact_snippets": "one prior first line treatment",
"criterion": "prior first line treatment",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "prior first line treatment"
}
}
]
}
]
},
{
"line": "* EGOC performance status of 0,1 or 2",
"criterions": [
{
"exact_snippets": "EGOC performance status of 0,1 or 2",
"criterion": "EGOC performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1",
"2"
]
}
]
}
]
},
{
"line": "* Men and women, 18 years of age and older",
"criterions": [
{
"exact_snippets": "Men and women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "18 years of age and older",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients having received more than one previous systemic chemotherapy regimen in any setting.",
"criterions": [
{
"exact_snippets": "Patients having received more than one previous systemic chemotherapy regimen",
"criterion": "previous systemic chemotherapy regimens",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "regimen"
}
}
]
}
]
},
{
"line": "* Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks",
"criterions": [
{
"exact_snippets": "Major abdominal surgery within 2 months",
"criterion": "major abdominal surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "months"
}
}
]
},
{
"exact_snippets": "any other surgery under general anesthesia within 4 weeks",
"criterion": "surgery under general anesthesia",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis)",
"criterions": [
{
"exact_snippets": "Unresolved occlusive or sub-occlusive intestinal disease",
"criterion": "occlusive or sub-occlusive intestinal disease",
"requirements": [
{
"requirement_type": "resolution",
"expected_value": false
}
]
},
{
"exact_snippets": "any significant chronic intestinal disease (e.g. ulcerative colitis)",
"criterion": "chronic intestinal disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Prior radiation to >=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment",
"criterions": [
{
"exact_snippets": "Prior radiation to >=30% of the bone marrow",
"criterion": "radiation to bone marrow",
"requirements": [
{
"requirement_type": "extent",
"expected_value": {
"operator": ">=",
"value": 30,
"unit": "%"
}
},
{
"requirement_type": "prior",
"expected_value": true
}
]
},
{
"exact_snippets": "radiation within 4 weeks prior to enrollment",
"criterion": "radiation",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 4 weeks prior to enrollment"
}
]
}
]
},
{
"line": "* Acute or chronic hepatitis",
"criterions": [
{
"exact_snippets": "Acute or chronic hepatitis",
"criterion": "hepatitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "type",
"expected_value": [
"acute",
"chronic"
]
}
]
}
]
},
{
"line": "* Known HIV infection",
"criterions": [
{
"exact_snippets": "Known HIV infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms",
"criterions": [
{
"exact_snippets": "baseline prolongation of QT/QTc interval ... QTc interval >450 ms",
"criterion": "QT/QTc interval",
"requirements": [
{
"requirement_type": "prolongation",
"expected_value": true
},
{
"requirement_type": "length",
"expected_value": {
"operator": ">",
"value": 450,
"unit": "ms"
}
}
]
}
]
},
{
"line": "* A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)",
"criterions": [
{
"exact_snippets": "A history of additional risk factors for Torsade de Pointes",
"criterion": "risk factors for Torsade de Pointes",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "heart failure",
"criterion": "heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "hypokalemia",
"criterion": "hypokalemia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "family history of Long QT Syndrome",
"criterion": "family history of Long QT Syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}